European Commission Approval of Bylvay (Odevixibat) for the treatment of Progressive Familial Intrahepatic Cholestasis

We are excited to hear that the EMA has approved Bylvay (Odevixibat) for the treatment of Progressive Familial Intrahepatic Cholestasis. This medication has helped many patients with symptoms of pruritus in clinical trials, and has been approved for use in all subtypes. According to their press release, “Albireo plans to directly commercialize Bylvay in the European Union (EU) and is prepared for a global launch with commercial, market access and medical affairs personnel already on the ground. This includes Germany, which has the largest EU market potential, with launch planned for September 2021, following price listing.” Congratulations to Albireo Pharmaceuticals! For the full press release, click here https://ir.albireopharma.com/news-releases/news-release-details/albireo-receives-european-marketing-authorization-bylvaytm

Albireo has prepared and FAQ for patients and families regarding the approval of Bylvay in Europe. For more information, please click the button below